Related Experiment Videos
[Prophylaxis of bipolar disorder].
Andrea Sterr1, Benedikt Amann, Heinz Grunze
1Psychiatrische Universitätsklinik der LMU München.
Psychiatrische Praxis
|March 3, 2006
Summary
Lithium is a primary treatment for bipolar disorder, but newer options like carbamazepine, valproate, lamotrigine, and atypical neuroleptics are emerging for complex cases. This review covers current maintenance therapy choices.
Area of Science:
- Psychopharmacology
- Neuroscience
- Clinical Psychiatry
Background:
- Lithium has been the cornerstone for bipolar disorder maintenance, offering mood-stabilizing and anti-suicidal benefits.
- Its efficacy is limited in bipolar disorder with atypical features such as psychotic symptoms or rapid cycling.
- This limitation necessitates exploring alternative and novel therapeutic strategies.
Purpose of the Study:
- To review the current landscape of psychopharmacological maintenance treatments for bipolar disorder.
- To highlight the limitations of lithium in specific bipolar disorder presentations.
- To summarize emerging and alternative treatment options.
Main Methods:
- Literature review of psychopharmacological treatments for bipolar disorder maintenance.
- Synthesis of current knowledge on established and novel therapeutic agents.
- Analysis of treatment efficacy based on disease presentation.
Main Results:
- Lithium remains a key treatment for classical bipolar disorder.
- Alternative medications including carbamazepine, valproate, and lamotrigine are considered for specific patient profiles.
- Atypical neuroleptics, thyroid hormones, and omega fatty acids represent innovative therapeutic avenues.
Conclusions:
- The treatment of bipolar disorder maintenance is evolving beyond lithium.
- Personalized treatment strategies are crucial, considering the specific manifestations of the illness.
- Further research into novel substances like omega fatty acids is warranted for comprehensive bipolar disorder management.